Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases by decoding complex biology into actionable insights. The company utilizes its Mirador360™ engine, which integrates biology, multi-modal data, and AI, to identify novel targets and optimal combination therapies. This approach accelerates the pipeline of potentially transformational therapies aimed at improving patient outcomes in I&I conditions.
Funding
$400M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective treatments for immune-mediated inflammatory and fibrotic diseases is challenging due to the complexity of these conditions and variability in patient response. Traditional drug development approaches often face difficulties in accurately identifying drug targets and predicting patient outcomes, leading to inefficiencies and delays.
Solution
Mirador Therapeutics is developing precision medicines for immunology and inflammation (I&I) by integrating human genetics and data science. The company's Mirador360™ precision development engine leverages multi-modal data and advanced analytics to accelerate the identification of novel drug targets and enable patient stratification. By analyzing extensive molecular profiles and genetic information, Mirador aims to develop targeted therapies that address the underlying causes of I&I diseases and improve treatment efficacy. This approach allows for a more accurate and efficient drug development process, potentially leading to first-in-class or best-in-class therapeutics for patients with chronic immune-mediated conditions.
Target Audience
The primary target audience includes patients suffering from chronic immune-mediated inflammatory and fibrotic diseases, as well as pharmaceutical companies seeking to develop more effective and targeted treatments for these conditions.
Features
- Mirador360™ precision development engine integrating human genetics and data science
- Access to a large repository of immune-mediated disease data, including over two million human molecular profiles
- Target validation using aggregated, de-identified genetic and phenotypic data
- Advanced analytics and AI capabilities for identifying new drug targets
- Patient stratification to predict individual responses to therapy